Pharvaris N.V.
PHVS evidence brief
What we can confirm
- Market Cap:
- $2.65B
What it means
What to watch
Prepared research question
What matters most for PHVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PHVS
Pharvaris N.V. is a Netherlands-based biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the on-demand and prophylactic treatment of hereditary angioedema (HAE) and related conditions, with a New Drug Application under FDA review and a PDUFA date of April 23, 2027 [sec · filed 2026-04-02][news · published 2026-08-12].
Key risk: No approved products
Market Cap
$2.65B
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Tracking 8 clinical trials for Pharvaris N.V..
Pharvaris N.V. is a Netherlands-based biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the on-demand and prophylactic treatment of hereditary angioedema (HAE) and related conditions, with a New Drug Application under FDA review and a PDUFA date of April 23, 2027 [sec · filed 2026-04-02][news · published 2026-08-12].
- Deucrictibant immediate-release (IR) capsule met primary and all key secondary efficacy endpoints with statistical significance in the pivotal Phase 3 RAPIDe-3 study for on-demand treatment of HAE attacks [sec · filed 2026-04-02].
- Pharvaris plans to submit an NDA to the FDA in the first half of 2026 for deucrictibant IR; as of August 2026, the NDA is under review with a PDUFA date of April 23, 2027 [sec · filed 2026-04-02][news · published 2026-08-12].
- The company reported cash and cash equivalents of €318 million as of June 30, 2026 [news · published 2026-08-12].
- CHAPTER-3, a pivotal Phase 3 study of deucrictibant extended-release (XR) for prophylaxis of HAE attacks, is ongoing with topline data expected in the third quarter of 2026 [news · published 2026-08-12].
- Pharvaris has no approved drugs and is heavily dependent on the success of deucrictibant IR and XR product candidates [sec · filed 2026-04-02].
What works
- Deucrictibant IR demonstrated a clinically differentiated profile in the RAPIDe-3 study, achieving statistical significance in the primary endpoint and all 11 secondary efficacy endpoints [sec · filed 2026-04-02].
- The company has a strong financial position with €318 million in cash and cash equivalents as of June 30, 2026, providing runway for ongoing development [news · published 2026-08-12].
- Management team includes leaders from the development of FIRAZYR and TAKHZYRO, and an inventor of icatibant serves as an advisor to the CEO [sec · filed 2026-04-02].
- Deucrictibant is an orally available product candidate with a clinically validated mechanism of action addressing a serious unmet medical need in bradykinin-mediated angioedema [sec · filed 2026-04-02].
What to weigh
- Pharvaris has no approved drugs and may never develop marketable products; its business depends heavily on the successful development and regulatory approval of deucrictibant IR and XR [sec · filed 2026-04-02].
- Clinical development timelines and costs are highly uncertain; any delays or negative results could materially adversely affect the company's business and financial condition [sec · filed 2026-04-02].
- The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future, with research and development expenses expected to increase in 2026 [sec · filed 2026-04-02].
- Regulatory approval is not guaranteed; factors such as interactions with the FDA and the ability to replicate efficacy in ongoing studies pose risks [sec · filed 2026-04-02].
From the filings
Quoted directly from source documents.
Deucrictibant IR met primary and all key secondary endpoints in Phase 3 RAPIDe-3 study
“Deucrictibant demonstrated a clinically differentiated profile by meeting the primary and all key secondary efficacy endpoints with statistical significance and was well tolerated.”
SEC filings · April 2, 2026
NDA for deucrictibant IR is under FDA review with PDUFA date of April 23, 2027
“Deucrictibant IR NDA under review by the FDA with PDUFA date of April 23, 2027”
News · August 12, 2026
Cash and cash equivalents of €318 million as of June 30, 2026
“Strong financial position with cash and cash equivalents of €318 million as of June 30, 2026”
News · August 12, 2026
Company has no approved drugs and is dependent on deucrictibant
“We do not have any drugs that have received regulatory approval and may never be able to develop marketable products.”
SEC filings · April 2, 2026
Catalyst timeline
- 2021-02-03 · Phase 2 start for acute treatment of HAE (PHA-022121) — Initiated a Phase II dose-ranging study for on-demand treatment of HAE attacks.
- 2022-04-19 · Phase 2 start for prophylaxis of HAE (PHA-022121) — Initiated a Phase II dose-ranging study for prophylactic treatment of HAE attacks.
- 2022-12-28 · Phase 3 start for acute treatment of HAE (PHA-022121) — Initiated a Phase II/III extension study for on-demand treatment of HAE attacks.
Risks & what to watch (4)›
Key risks
- No approved products — Pharvaris has no approved drugs and may never develop marketable products; business depends on deucrictibant IR and XR [sec · filed 2026-04-02].
- Regulatory approval uncertainty — NDA under FDA review; any delays or negative interactions could materially affect business [sec · filed 2026-04-02].
- Clinical trial risks — CHAPTER-3 and other studies may not replicate prior efficacy; timelines and costs are highly uncertain [sec · filed 2026-04-02].
- Increasing operating losses — Company expects significant expenses and increasing operating losses for the foreseeable future [sec · filed 2026-04-02].
What to watch
- Topline data from CHAPTER-3 pivotal Phase 3 study of deucrictibant XR for prophylaxis of HAE attacks expected in 3Q2026 [news · published 2026-08-12].
- PDUFA date for deucrictibant IR NDA is April 23, 2027; FDA review outcome is a key milestone [news · published 2026-08-12].
- MAA validated by the EMA in July 2026; European regulatory progress should be monitored [news · published 2026-08-12].
- Enrollment in CREAATE study for AAE-C1INH treatment; data may expand pipeline [news · published 2026-08-12].
Sources: Catalysts · News · SEC filings · Generated October 10, 2026 · How we verify sources →
Run Pharvaris N.V. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pharvaris N.V. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
110
Total value held
$1.66B
| Holder | Shares | Value |
|---|---|---|
| general atlantic, l.p. | 8,031,252 | $226.9M |
| fmr llc | 6,284,472 | $177.5M |
| foresite capital management iv, llc | 4,778,581 | $135.0M |
| venbio partners llc | 4,639,304 | $131.1M |
| viking global investors lp | 3,653,310 | $103.2M |
| eqt fund management s.a r.l. | 3,424,609 | $96.7M |
| deerfield management company, l.p. | 3,126,042 | $88.3M |
| bain capital life sciences investors, llc | 2,675,509 | $75.6M |
| wellington management group llp | 2,118,900 | $59.9M |
| commodore capital lp | 1,918,970 | $54.2M |
Showing top 10 of 110 institutional holders of Pharvaris N.V.. Open the full 13F history after sign-in.
Short Interest
as of May 22, 2026- % of float
- 2.0%
- Days to cover
- 3.8
- Shares short
- 1,051,478
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PHVS short interestFrequently asked questions
What is the AI investment thesis for Pharvaris N.V.?
Pharvaris N.V. is a Netherlands-based biopharmaceutical company developing deucrictibant, an oral bradykinin B2 receptor antagonist, for the on-demand and prophylactic treatment of hereditary angioedema (HAE) and related conditions, with a New Drug Application under FDA review and a PDUFA date of April 23, 2027 [sec · filed 2026-04-02][news · published 2026-08-12].
Who is the CEO of Pharvaris N.V.?
Mr. Berndt Axel Edvard Modig CPA, M.B.A. is the chief executive officer of Pharvaris N.V. (PHVS).
Where is Pharvaris N.V. headquartered?
Pharvaris N.V. (PHVS) is headquartered in Zug, Switzerland.
What therapeutic areas does Pharvaris N.V. focus on?
Pharvaris N.V. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.